immupharma plc said friday that its firsthalf pretax loss narrowed inline with expectations amid lower expenses and that it is reviewing recommendations from the us food and drug administration for its lupus treatment the pharmaceutical company said pretax loss narrowed to 18 million pounds 20 million from a restated loss of gbp39 million a year prior administrative and sharebased expenses both significantly narrowed and the company had recorded a oneoff exceptional loss of gbp846792 in the prior year immupharma didnt declare any revenue for the period last year it posted revenue of gbp23531 the company also said it has been reviewing in detail a written response and recommendations from the us food and drug administration with its us partner for its lupuzor lupus treatment further details once finalized will be communicated to the market the fda had provided dosing guidance and advice on an amended study protocol to improve the regulatory outcome moving forward we remain focused on creating a robust and successful company that with a diversity of assets will build future value for our shareholders chief executive and chairman tim mccarthy said shares at 0728 gmt were up 006 pence or 21 at 29 pence